Nasdaq · Healthcare
Arbutus Biopharma Corp (ABUS)
As-reported financials and recent SEC filings for Arbutus Biopharma Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$14.1M
Net income
$-33.5M
Net margin
—
Diluted EPS
$-0.17
ROE
-43.7%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-38.2M | $-76.3M | $-78.1M | $-65.5M | $-73.5M |
| Net income | $-33.5M | $-69.9M | $-72.8M | $-69.5M | $-76.2M |
| Diluted EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →S-82026-06-05
View on EDGAR →8-K2026-05-27
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →10-Q2026-05-13
View on EDGAR →8-K2026-05-13
View on EDGAR →SCHEDULE 13D/A2026-04-28
View on EDGAR →Largest Healthcare peers
Go deeper on ABUS
Search Arbutus Biopharma Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.